Track record · closed signal

Eli Lilly and Company (LLY) — closed signal from May 27, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on August 25, 2026 — +14% at the close.

Predicted vs. what happened

LLY price · publication thesis → realized outcomesplit-adjusted

$1,025.00 – $1,070.00Entry zone — fair-value band

$1,081.97Published — price the day we called it

$1,190.16Target — the price the thesis aimed for

$1,292.65Peak — highest point inside the window, not a realized return

$1,233.66Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 30 days.

At window close

+14%

realized, from the publication price to the last close inside the window

Peak gain

+19.5%

peak, from the publication price — not a realized return

S&P 500, same window

+2.3%

SPY over the identical days, dividend-adjusted

Window close

$1,233.66

last close inside the window, ended August 25, 2026

Peak price

$1,292.65

peak on August 19, 2026 — not a realized return

Days to target

The thesis — published May 27, 2026

Predicted growth

+10%

over the measurement window

Target price

$1,190.16

the price the thesis aimed for

Entry zone

$1,025.00 – $1,070.00

the fair-value band we waited for

Price at publication

$1,081.97

published May 27, 2026

Confidence

70%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Eli Lilly is a high-quality healthcare growth company driven by its obesity and diabetes businesses and a deep pipeline. New retatrutide results made the long-term medical story stronger and kept investor focus on next-generation incretin drugs. Near-term risk is higher because the stock is trading above preferred levels and volume is light.

Primary drivers

Retatrutide results boost confidence in next-wave obesity drugs
Diabetes and obesity franchises make earnings more predictable
Large, diverse pipeline supports sustained healthcare growth
Current pricing and light volume mean patience and price discipline matter

How it played out

LLY: target reached in 30 days

Lyra published LLY at $1,081.96 with expected growth of 10% and a target of $1,190.16. The thesis pointed to its obesity and diabetes businesses, retatrutide results, and a broad pipeline. It also noted that the shares were above the preferred entry range and trading volume was light.

The shares reached the target in 30 days. They later peaked at $1,292.65 on August 19, a gain of 19.5% from publication. LLY ended the window at $1,233.66, still above the target. The published thesis played out and exceeded its stated price objective.

What happened during the window

On June 7, Lilly reported results from analyses of its oral obesity drug studies in women at different stages of menopause. On August 5, the company reported second-quarter revenue growth of 48% and raised its full-year revenue guidance.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All LLY signals